NCT01661283 - SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

June 30, 2017

Study Completion Date

December 31, 2017

Conditions

Malignant Peripheral Nerve Sheath TumorsMPNSTSarcoma

Interventions

DRUG

everolimus

10 mg tablet once daily

DRUG

bevacizumab

10 mg/kg dose every 14 days

Trial Locations (12)

Children's Hospital of Philadelphia, Philadelphia

Pennsylvania Oncology Hematology Associates, Philadelphia

Children's National Medical Center, Washington D.C.

Johns Hopkins, Baltimore

University of Michigan, Ann Arbor

University of Iowa, Iowa City

Ann and Robert Lurie Children's Hospital of Chicago, Chicago

Washington University in St. Louis, St Louis

University of Alabama at Birmingham, Birmingham

National Cancer Institute, Bethesda

Massachusetts General Hospital, Boston

Cincinnati Children's Hospital Medical Center, Cincinnati